Understanding Opioid Addiction and. Medication Assisted Treatment for. Families in the Child Welfare System
|
|
- Robyn Parker
- 5 years ago
- Views:
Transcription
1 Understanding Opioid Addiction and Medication Assisted Treatment for Families in the Child Welfare System Medicine Jason B. Fields, MD, FASAM Associate Medical Director, DACCO Behavioral Health, Inc. President of the Florida Society of Addiction Medicine Linda Mann, LCSW, CAP Director of Family Services DACCO Behavioral Health, Inc. 1
2 Scope of the Problem 90 Americans die of an opioid overdose daily In 2016, overdose deaths exceeded 59, the largest annual increase ever recorded in the United States Opioids thus have become the leading cause of death among Americans under age 50, and two-thirds of the deaths involve a prescription opioid
3 Overview of the Problem 2.1 million people in the U.S., ages 12 and older, had opioid use disorder (OUD) involving prescription opioids, heroin, or both in 2016 Opioid-related emergency department (ED) visits nearly doubled from 2005 to 2014 Opioid-related inpatient hospital stays increased 64% nationally from 2005 to 2014 Opioid addiction is linked with high rates of illegal activity and incarceration.
4 Current Treatment Gap Along Opioid Use Disorder Cascade of Care
5 Review of Medications
6 Introduction to TIP 63, Medications for OUD Reviews the three FDA-approved medications used to treat OUD methadone, naltrexone, and buprenorphine along with strategies and services to support recovery for people with OUD OUD medications are more effective than treatment with placebo or no medication in: Reducing illicit opioid use Retaining people in treatment OUD medication can be taken on a short- or long-term basis, including as part of medically supervised withdrawal or maintenance treatment
7 Purpose of TIP 63 Provides guidance for healthcare professionals and addiction treatment providers on: Appropriate prescribing practices for the three FDAapproved medications used to treat OUD. Effective strategies for supporting patients using medication for the treatment of OUD. Educates patients, families, and the general public about the benefits of OUD medications and how they work.
8 Purpose of TIP 63 The TIP series supports SAMHSA s mission by providing sciencebased best-practice guidance to the behavioral health field. This TIP reflects relevant clinical and health service research and addresses experience and implementation requirements for delivery of OUD medication Science demonstrates the effectiveness of medication treatment for OUD. Randomized control trials have shown that methadone, extended-release naltrexone (XR-NTX), and buprenorphine were more effective in reducing illicit opioid use than no medication Methadone and buprenorphine treatment also have been associated with reduced risk of overdose death
9 Introduction to Pharmacotherapy Overview of FDA-approved medications used to treat OUD. How they work Efficacy Expanding access to pharmacotherapy is an important clinical and public health strategy Specialty drug treatment programs should integrate pharmacotherapy. Requirements and regulations. Opioid treatment programs (OTPs) Waiver for buprenorphine Risk Evaluation and Mitigation Strategy (REMS) for buprenorphine implants and extended release buprenorphine
10 Introduction to Pharmacotherapy Medically supervised withdrawal: Often followed by relapse (Gruber et al., 2008; Weiss et al., 2011). Psychosocial strategies (e.g., contingency management) can reduce risk of relapse (Amato et al., 2011). Necessary prior to naltrexone treatment. Continue medication as long as benefits outweigh risks: Discontinuing medication is associated with relapse (Lee et al., 2016; Sees et al., 2000). Inform patients of risks of discontinuing medication.
11 Assessment of OUD Assess patients for OUD using DSM-5 criteria if they: spontaneously disclose opioid misuse. screen positive for opioid misuse. show signs or symptoms of opioid misuse. The extent of further assessment depends on the provider s ability to treat patients directly.
12 Providers Not Offering Pharmacotherapy Focus on medical assessment. Diagnose OUD. Discuss treatment options. Make a treatment referral. Provide overdose prevention information, naloxone prescription, and information on accessing sterile injection equipment. Make a follow-up appointment.
13 Providers Offering Pharmacotherapy Check Prescription Drug Monitoring Program (PDMP) Medical, mental health and substance use history Current medications Physical exam Assess opioid withdrawal, intoxication, & injection sites Drug testing Laboratory tests (e.g., pregnancy, liver function, HIV, hepatitis) Make diagnosis (DSM-5)
14 Treatment Planning Share the OUD diagnose and obtain patient feedback Use shared decision-making strategies Medication: Yes or No Which medication? Where to receive medication? Primary care. Specialty drug treatment program. Outpatient, OTP, residential. Which additional services are needed and wanted? Behavioral health. Self-help meetings.
15 Patients Not Ready to Engage in Treatment Provide information on: Reducing injection drug risk. Overdose prevention. Provide naloxone prescription. Make a follow-up appointment to mental health, medical, addiction treatment, & recovery support services as needed. Provide resource list
16 Methadone Methadone treatment is the most studied OUD treatment. World Health Organization considers methadone an essential medication (WHO, 2015). Clinical trials and meta-analyses show that methadone treatment is superior to treatment with placebo and to no treatment (e.g., waiting list or supervised withdrawal with methadone) in reducing illicit opioid use (Mattick et al., 2009).
17 Regulatory Issues In the US, methadone treatment must be delivered through licensed and accredited Opioid Treatment Programs (OTPs). Federal regulations stipulate admission criteria & services that must be provided (42 CFR 8.12). Admission criteria: >1 year of opioid addiction prior to admission. Can be waived for pregnant women; patients within 6 months of release from incarceration; former patients within 2 years of discharge. Youth < 18 years of age must have: parental consent. >2 unsuccessful prior treatments.
18 Pharmacology Review methadone s pharmacology: Full mu-opioid agonist. Wide individual variability in half-life (8 to 59 hours). 5 half-lives to reach steady state (average is about 5 days). metabolized largely by CYP450 3A4 enzymes. Clinical implications: Dosing must be individualized. Start at low dose and increase slowly. Adequate dose: No withdrawal symptoms for 24 hours. Reduces or eliminates craving. Blunts or blocks euphoria from illicit opioids.
19 Review of Medication Managment Precautions: Including QTc prolongation Respiratory depression Drug interactions, especially benzodiazepines and alcohol Side effects Assessment Dosing considerations Patient education
20 Comparative Effectiveness Cochrane Review of RCTs comparing methadone v. buprenorphine (Mattick et al., 2014): Methadone patients retained longer in treatment Methadone and buprenorphine equally effective in reducing illicit opioid use No RCTs comparing methadone with long-acting buprenorphine formulations No RCTs comparing methadone with XR-NTX
21 Methadone Dose Induction Considerations First methadone dose: Opioid tolerant patients: between 10 and 30 mg Use lower dose range (10-20 mg) for patients: >60 years old with lower levels of opioid tolerance based on recent history of use treated with medications that: are sedating increase methadone serum levels (or stop taking ones that decrease levels) Disorders that cause: hypoxia hypercapnia cardiac arrhythmia
22 Methadone Dosing Considerations Weeks 1-2: Avoid sedation at peak serum levels (2-4 hours after dose). Gradually extend the time without opioid withdrawal and craving Individualize dosing based on careful assessment of patient response ASAM panel recommended: 5 mg increase about every 5 days (Baxter et al., 2013) American Pain Society/CPDD panel recommended: 5-10 mg increase about every 3-4 days (Chou et al., 2014) Weeks 3-4: Suppress opioid withdrawal Reach a dose that will blunt the euphoric effect of illicit opioids Dose can be increased by 5 mg every 3-4 days
23 Special Dosing Considerations First dose for patients without current opioid tolerance: An alternative for patients not wanting XR-NTX (or buprenorphine). Former OTP patients fearing relapse Incarcerated patients with history of OUD: prior to release or upon returning to treatment begin with 5 mg per day. increase slowly by 5 mg increments every 5 7 days (Kinlock et al., 2008)
24 Duration of Methadone Treatment Longer stays are associated with better outcomes (Timko et al., 2016): Leaving methadone treatment is associated with increased risk of overdose death (Sordo et al., 2017) Patients should continue in treatment as long as they wish to and as long as the benefits outweigh the risks Dose tapering request should prompt a risk benefit discussion Plan for dose tapering should be gradual and individualized: Offer increased psychosocial and recovery supports. Stop taper if indicated and desired by patient
25 Buprenorphine On WHO s list of essential medications DATA 2000 applies only to buprenorphine formulations FDA approved for OUD treatment Physicians, nurse practitioners and physician assistants 6-month implant (Probuphine ): additional training required per FDA REMS for ordering and inserting/removing, not dispensed directly to patient Monthly injection (Sublocade ): special certification required persuant to FDA-approved REMS, not dispensed directly to patient
26 Duration of Treatment Continued medication treatment associated with better outcomes compared to medically supervised withdrawal Expert TIP panel:...supports maintaining patients on medication for years, decades and even a lifetime if patients are benefiting. Does not recommend medically supervised short-term withdrawal alone because of high rates of return to illicit opioid use Recommends discontinuing dose reductions and allowing for dose increases if patient destabilizing, prompt re-entry to treatment, encouraging psychosocial adjuncts
27 Pharmacology Review of buprenorphine pharmacology High affinity, partial opioid agonist, improved safety profile vs. full agonists Wide individual variability in pharmacokinetics: Peak plasma concentrations after a first dose of transmucosal (TM) product occur between 40 min-3.5 hours after dosing (Elkader et al., 2005) Long and variable elimination half-life from hours (Kuhlman et al., 1998) TM products: long half-life and partial agonist properties allow for less than daily dosing (e.g., doubling the daily dose once stable and giving on alternate days, 12 mg daily = 24 mg every other day; Marsh et al., 2005)
28 New Transmucosal Formulations New transmucosal (TM) formulations with improved bioavailability Ex: Zubsolv 5.7/1.4, Bunavail 4.2/0.7, Suboxone film 8/2, generic 8/2 Suboxone tablets all with bioequivalent buprenorphine exposures compared to 8/2 mg Suboxone tablet (that is no longer available) Goals of dosing of all TM formulations: Eliminate withdrawal Reduce or eliminate opioid craving. Provide effective blockade when there is illicit opioids use (patient reports diminished positive effects from the use of illicit opioid) Be well-tolerated
29 Review of Transmucosal Dosing Induction: In-office or at home. Home induction can be safe and effective (Gunderson et al, 2010; Lee et al., 2014) Individualize dosing several factors to consider including level of physical dependence For those with current physical dependence, initiate when in withdrawal with an initial 2-4 mg dose of bup/nx. FDA label recommends a maximum dose of 8 mg on day 1 and 16 mg on Day 2. Remember some patients stabilize on lower doses. Scant data to support more than 24 mg daily For those not currently physically dependent, initiate at lower doses (e.g., 1 mg with slow incremental increases, holding for sedation; Vocci et al. 2015)
30 New Long-Acting Formulations 6-month implant: approved in 2016 for clinically stable patients on buprenorphine(bup)/naloxone (nx) <8 mg / day for at least 90 days Monthly injection: recently approved for moderatesevere OUD after initiation with TM bup/nx with at least 7 days of dose adjustment
31 New Long Acting Formulations: Implant 6 month subdermal implants: Dose is 4 implants (each containing 80 mg buprenorphine), inserted in upper arm Peak plasma concentration 12 hours after insertion Removed & replaced after 6 months, wound care check within 1 week of implant and removal, office visits at least monthly to assess continued stability Consider TM supplementation if destabilize 17.9% required in Phase 3 RCT but low dose (2/0.5) and for short periods (Rosenthal et al. 2016) In a non-inferiority trial, improved abstinence rates compared to SL bup/nx (Rosenthal et al., 2016) Approved for two rounds of implants Serious adverse events: uncommon but possible including migration and nerve damage, potential for extraction and misuse. USE ONLY IN STABLE PATIENTS Limited data in pregnancy
32 New Long Acting Formulations: Injection Monthly subcutaneous abdominal injection: Refrigerate, keep at room temperature for at least 15 minutes prior to injection Dose: Months one and two 300 mg, month 3 and thereafter 100 mg (may increase if clinically indicated) Do NOT rub or massage or let belts/waistbands rub against Obtain baseline liver function tests(lfts) and monitor monthly, particularly with 300 mg dose Most common side effects were: nausea, vomiting, headache, constipation, increased LFTs, tiredness, injection site itching and pain. Uncommon: need for surgical removal of injection Limited data in pregnancy. Contains excipient, N-Methyl- 2pyrrolindone, that has reported adverse fetal effects in animal studies
33 Regulatory Considerations Waiver for physicians: 30, 100, 275 patients. Additional proactive reporting requirements for medical doctors (MDs) with approval to treat 275 patients. Requires on-call service and documented diversion control plan. Waiver for nurse practitioners (NPs) and physician assistants (PAs): 30 and 100 patients. 24 hours of training. Unique requirements for new long-acting formulations.
34 Sample Forms Buprenorphine treatment agreement Patient urine drug screen and medication count monitoring form: to assist with conduct of random urine and medication counts Pharmacy medication count form: sample of how to collaborate with pharmacies, particularly when patients may live closer to pharmacy than clinic. Sample goal-setting and coping strategy forms Checklist for induction and maintenance when using TM buprenorphine
35 Naltrexone Oral naltrexone not widely used: low acceptance and poor adherence Extended release naltrexone (XR-NTX, Vivitrol ): efficacy for preventing return to illicit opioid use after period of illicit opioid abstinence (Krupitskyet al., 2011; Lee et al., 2016): Prior to release from incarceration or residential treatment Following medically supervised withdrawal No special regulatory requirements.
36 Pharmacology Oral: peak concentrations within 1-2 hrs, half-life ~4 hrs XR-NTX: transient peak concentration 2 hrs after injection & then another at 2-3 days after injection. Concentrations gradually diminish after 14 days Elimination half-life is 5-10 days Can precipitate opioid withdrawal: Typically patients must wait ~7-10 days after a short-acting or days after a long-acting opioid to initiate XR-NTX Active area of research to effectively and expeditiously facilitate initiation of naltrexone
37 Comparative Effectiveness None comparing XR-NTX to methadone or to new longacting buprenorphine formulations Compared to sublingual buprenorphine/naloxone: Among inpatients undergoing medically supervised withdrawal in USA (n=580) XR-NTX had higher return to illicit opioid use over 24 weeks outpatient study due to difficulty initiating XR-NTX (Lee et al., 2018) Among the groups that were able to start the two medications, there were no significant differences in relapse 12-week outpatient non-inferiority trial in Norway (n=159), XRNTX non-inferior to buprenorphine/naloxone (Tanum et al., 2018)
38 XR-NTX Must have no signs of opioid withdrawal before administration, negative opioid test, consider naloxone challenge prior to initiating naltrexone Dose: intramuscular 380 mg monthly (or every 4 weeks) injection into upper outer quadrant of buttock. Alternate sides every month. Proper technique critical to avoid serious injection site reactions. Follow package insert/visual aids provided Refrigerated, keep at room temp for ~45 min before administration Assess baseline LFTs and periodically (e.g., 6 and 12 months intervals)
39 Sample Forms & Further Discussions Patient counseling tool for XR-NTX. Sample treatment agreement for XR-NTX. Goal setting and coping strategies forms also applicable. Discontinuation discussion question and points for patient and provider.
40 Efficacy of MAT and Relapse Rates
41 Bottom Line! In both controlled and retrospective studies, the success rate for most medications is between 40 and 60 % (one or two years, Connery 2015) When patients come off the medications, they relapse (Weiss 2011, Fiellin 2014) Relapse may be associated with an increased chance of overdose and death (Kakko 2003)
42 Ball 1988: Reduction in IVDU with Methadone
43 Ball 1988: Reduction in IVDU with Methadone
44 Buprenorphine Long-Term Follow Up: Fiellin, 2008
45
46 No XRNTX: Abstinence 40%
47 XRNTX: Abstinence 50%
48 Ball 1988: Resumption of IVDU After Tapering Off Methadone
49 Ball 1988: Resumption of IVDU After Tapering Off Methadone
50 Buprenorphine Taper VS. Maintenance 40 heroin addicts were started on buprenorphine/naloxone. 20 were detoxed off and offered counseling. 20 were kept on buprenorphine/naloxone and offered counseling. A year later.
51
52
53 Luty 2003: Opioid Detox During Pregnancy 101 women underwent detox during pregnancy 40 successfully detoxed. No adverse fetal effects documented BUT:
54 Luty 2003: Opioid Detox During Pregnancy 101 women underwent detox during pregnancy 40 successfully detoxed. No adverse fetal effects documented BUT: only 1 of 101 abstinent at delivery!
55 Can You Taper of Buprenorphine Without Relapse?
56 Can You Taper of Buprenorphine Without Relapse? 654 patients enroll on buprenorphine for 2 weeks. 50%stay abstinent. They are tapered off and over 90% relapse. 360 remain, they go back on buprenorphine for 12 weeks, 50% stay abstinent. They taper off and 90+% relapse. Moral of the story: medications work as long as you take them. Weiss, 2011
57 42 Months Later.
58 Outcomes? About half were reached by phone No urine drug screens were done; interviews only 32% were abstinent without M.A.T. 29% were abstinent WITH M.A.T. 8% were using while on M.A.T. 31% were using without M.A.T. Conclusion: M.A.T. was twice as successful
59 Other Concerns about Buprenorphine It can be abused (mostly for withdrawal; Kenney 2017) It is unsafe when combined with sedatives & alcohol. Adding naloxone (Suboxone/Zubsolv) doesn t help (Cohier2014) It is an opioid. Relapse rates after detox exceed 90%. (Weiss, 2011)
60 Opioid use prevention effects weaned after treatment discontinuation : Lee 2017 NEJM
61 Conclusions MAT is effective-at decreasing opioid use. Stopping MAT will usually (?) result in relapse & potentially increased chance of death. (Sordo, 2017) Why would you expect otherwise? Methadone is better at keeping you in treatment. Buprenorphine has a superior safety profile. (Mattick2014) Vivitrol (injectable naltrexone) is effective at reducing opioid use. (Kruptisky2011); it doesn t work when you don t take it (Lee 2016)
62 Successful Efforts!
63 Successful Rhode Island Project!
64 CDC Recommends Use of MAT for Patients with OUD
65 Science = Solutions: Improving Addiction Treatment
66 CDC s New Study Enrolling Through January 2019
67 Frequently Heard MAT Myths in the Child Welfare System
68 Frequently Heard MAT Myth # 1 MAT patients are still using (continuing drug use) and not really in recovery. They re just substituting one drug for another. MAT is a medical intervention used to treat symptoms of opioid addiction, similar to a SSRI treating depression, also a brain disorder. Buprenorphine and methadone are not street heroin/opioid substitutes patients withdrawal symptoms and cravings are ameliorated and no euphoria/ high is produced.
69 Frequently Heard MAT Myth # 2 The lower dose of Methadone or Buprenorphine, the better. An effective dose is determined by the patient's presenting needs. If the maintenance dosage is too low the patient will continue to experience withdrawal symptoms and may then use opioids. Dosing is an individualized medical decision.
70 Frequently Heard MAT Myth # 3 Parents in the child welfare system should only be on MAT a max of 12 months. Accepted practice that 12 months is necessary for methadone maintenance to be effective, 9 months for buprenorphine and 5 months for naltrexone. Longer treatment usually recommended. A detrimental consequences of leaving MAT are illustrated by greatly increased death rates following discharge.
71 Frequently Heard MAT Myth # 4 Parents should to be off all drugs, including Methadone, in order to be reunified. Discontinuing methadone treatment places the parent at elevated risk for relapse to illicit opiate use and associated high-risk factors, including unsafe injection practices and illegal behavior to support using. These factors can significantly increase the risk of abuse or neglect to children in the custody of these parents. The decision to require methadone detoxification should be measured carefully and based upon sound clinical principles rather than the stigma associated with methadone treatment.
72 The Yin & Yang of MAT Some patients will divert and misuse, even sell the medications on the street. Unfortunately, these medications do not prevent the concurrent use of other drugs including illegal opiates, cannabis and benzodiazepines. Crushing, snorting and injecting the medications occurs. The benefits of MAT greatly outweigh the drawbacks.
73 Strategies to Overcome Resistance to MAT
74 Approaches to Educating Child Welfare Professionals Dissemination of MAT current research & practice information on multiple system levels. Whenever and wherever opioid misuse is discussed MAT as an option. Share case information in SA/CW cross-system, reciprocal staffings. Cross-system trainings with case managers and supervisors.
75 Approaches to Educating Child Welfare Workers and Administrators Presentations to key community stakeholders for example, DACCO provides MAT training to various community agencies and county child welfare committees. Tours of medically monitored, licensed Methadone programs to dispel myths to Judges, court administration, CBC s and CPI leaders, case managers, etc..
76 Responding to Dependency Judges & Court Administrators Accurate program, research & practice information distributed to judges & court administrators. 1:1 meetings with judges to facilitate communication & strengthen collaboration. MAT trainings with court staff. Develop MAT progress reports to courts, as needed, to assist and indirectly educate court staff. SA case managers in courts to communicate accurate client & program information.
77 Suggestions for Enhancing Services for MAT Patients
78 Family Dependency Treatment Court MAT Case Review Form This client is medically monitored by Medical staff. The following treatment was provided to the above client and meets medical protocol: NO YES Current Medication and Dose: Methadone at mg. Suboxone at mg. Admission: New Methadone client admitted on with initial dose of 30 mg. Up to four 5 mg. increases as needed for withdrawal ordered. (Please note that blockade actually doesn t start until 60 mg.) A new Suboxone client admitted on with initial dose of 4 mg. and additional 4 mg. dose after one hour if needed. Up to three 2 mg. doses as needed for withdrawal ordered. Client transferred from another clinic and receiving their established dose of Methadone/Suboxone as prescribed at their previous clinic.
79 Family Dependency Treatment Court MAT Case Review Form Dose increased because of: Nausea Headache Cramps Craving Doctor approval of counselor request / treatment plan Other: Dose decreased because of: Sleepiness Physical illness Medical problems High methadone levels Other: Client missed 3 days in a row, and their dose is more than 30 mg., so his/her dose was automatically cut by 1/3 to. Client missed 4 days in a row and their dose is more than 30 mg., so his/her dose was automatically cut by 2/3 to. Client missed 5 days in a row and was required to meet with the Physician to resume dosing. They have not met OR met with the Physician.
80 Family Dependency Treatment Court MAT Case Review Form Client is currently a candidate for detox: NO YES Nurse Signature/date required Physician Signature/date required Form faxed to court and program case manager present to answer questions.
81 Treatment Status Reports Includes: Compliance Medical compliance Attendance & participation Positive changes, accomplishments and /or challenges in treatment Scheduled visitation Drug screen compliance (missed?) & results (abnormal or rejected?) Current prognosis Provider Recommendations
82 Suggestions for Child Welfare Case Management of Parents Enrolled in MAT Learn the basics of MAT to more effectively manage case. Remain non-judgmental, open minded and supportive. Have patient sign Release of Information for MAT provider so as to facilitate open communication. Tour a MAT program and ask for an explanation of their dosing & drug screening practices.
83 And the work continues
84 Continuing MAT Challenges Cost - Medicaid pays for Methadone and Buprenorphine, otherwise client must self-pay. Medicaid currently pays for Methadone but not Suboxone or Vivitrol Appropriate MAT training to child welfare and court staff due to time, cost restraints and turn-over. Coordination of services that client is concurrently engaged in. Other SA TX providers not embracing MAT.
85 RESOURCES Florida Alcohol & Drug Abuse Association Hazelden National Center on Substance Abuse & Child Welfare National Institute on Drug Abuse (NIDA) Treatment Improvement Exchange www. treatment.org US Dept. of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment csat.samsha.gov US Dept. of Health and Human Services, Substance Abuse and Mental Health Services Administration
86 QUESTIONS???
Initiation of MAT for Opioid Use Disorder in the Hospitalized Patient and ER Setting: Promoting Best Outcomes in the Wake of an Opioid Crisis
Initiation of MAT for Opioid Use Disorder in the Hospitalized Patient and ER Setting: Promoting Best Outcomes in the Wake of an Opioid Crisis Sponsored by the Florida Alcohol and Drug Abuse Association
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More information6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder
Rethinking Medication Treatment for Opioid Use Disorder International Conference on Opioids June 10, 2018 Dustin Patil, MD Fellow, Addiction Psychiatry Boston Medical Center John Renner, MD Professor of
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationSUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication
More informationSubstance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January
More informationNALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018
NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications
More informationTreatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
More informationFY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
More informationMedication Assisted Treatment for Opioid Use Disorders and Veteran Populations
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More informationOverview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone
Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Alexander Y. Walley, MD, MSc Associate Professor of Medicine Director, Addiction Medicine Fellowship Boston University
More informationMedications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC
Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are
More informationMethadone Maintenance 101
Methadone Maintenance 101 OTP/DAILY DOSING CLINICS - ANDREW PUTNEY MD Conflicts of Interest - Employed by Acadia HealthCare 1 Why Methadone? At adequate doses methadone decreases opioid withdrawal symptoms
More informationDisclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.
Evolving Treads in Medication Assisted Treatment Christopher J Davis D.O. CAADC, FASAM Medical Director, The Ranch of Pennsylvania Medical Director, Pyramid Healthcare Diplomate of The American Board of
More informationPrepublication Requirements
Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals
More informationAn overview of Medication Assisted Treatment (MAT) and acute pain management on MAT
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)
More informationMAT in the Corrections Setting
MEDICATION ASSISTED TREATMENT AND CORRECTIONS Frank Filippelli, DO, PhD September 2017 MAT in the Corrections Setting Who Does This Affect? What is MAT and What is the Evidence of Efficacy? Emphasis on
More informationCorporate Medical Policy
Corporate Medical Policy Buprenorphine Implant for Treatment of Opioid Dependence File Name: Origination: Last CAP Review: Next CAP Review: Last Review: buprenorphine_implant_for_treatment_of_opioid_dependence
More informationThe Opioid Crisis: What Can Physicians Do About It?
The Opioid Crisis: What Can Physicians Do About It? Richard S. Schottenfeld, M.D. Professor and Chair, Department of Psychiatry and Behavioral Sciences 2018 Louis J. Kolodner Memorial Lecture Disclosures
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationShawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine
[Patient-focused, evidence-based addiction treatment] Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine BrightView Health All Rights Reserved www.brightviewhealth.com
More informationManagement Options for Opioid Dependence:
Management Options for Opioid Dependence: Policy Implications and Recommendations Dan Ollendorf, PhD Sarah Jane Reed, MSc New England CEPAC Goal: To improve the application of evidence to guide practice
More informationThe CARA & Buprenorphine Prescribing for APNs & PAs
The CARA & Buprenorphine Prescribing for APNs & PAs William J. Lorman, JD, PhD, MSN, PMHNP-BC, CARN-AP FIAAN Assistant Clinical Professor, Drexel University, Philadelphia, PA V. P. & Chief Clinical Officer,
More informationMedication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs
More informationTREATING OPIOID ADDICTION IN HOMELESS POPULATIONS
TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS Challenges and Opportunities Providing Medication Assisted Treatment (Buprenorphine) August 18, 2016 SPEAKERS TODAY Nilesh Kalyanaraman, MD, Chief Health
More informationMedications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?
Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives
More information(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)
Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationClosing the Loop in Treating Opioid Addiction:
Closing the Loop in Treating Opioid Addiction: Integrating MAT into Prison and Jail Health Systems May 9, 2018 Webinar Housekeeping All lines are muted This session will be recorded To ask a question:
More informationMedication Assisted Treatment
Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationClinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationMedication Assisted Treatment. Nicole Gastala, MD
Medication Assisted Treatment Nicole Gastala, MD Objectives Training Goals: To enhance the understanding of the participants in use of medication assisted therapy To increase the knowledge of participants
More informationAgenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model
Agenda 1 Opioid Addiction in the United States 2 Evidence-based treatments for OUD OUD Treatment: Best Practices 4 Groups: Our Model 2 Groups is a national network of clinics providing affordable, evidencebased
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
More informationUnderstanding Medication in Addiction Treatment for Drug Court Participants
Understanding Medication in Addiction Treatment for Drug Court Participants Introduction This pocket guide is for drug court participants who may be prescribed or considering medication as a part of addiction
More informationOpioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
More informationBrief History of Methadone Maintenance Treatment
METHADONE Brief History of Methadone Maintenance Treatment Methadone maintenance treatment was on the cusp of the social revolution in the sixties. Doctors and public health workers had concluded what
More informationSuboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description
More informationRevised 9/30/2016. Primary Care Provider Pain Management Toolkit
Revised 9/30/2016 Primary Care Provider Pain Management Toolkit TABLE OF CONTENTS 1. INTRODUCTION Page 1 2. NON-OPIOID SERVICES &TREATMENTS FOR CHRONIC PAIN Page 2 2.1 Medical Services Page 2 2.2 Behavioral
More informationMedication Assisted Treatment:
Medication Assisted Treatment: A Training For Multidisciplinary Addiction Professionals Module III Medications 101 Goals for Module III This module reviews the following: Overview of three medications
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationAddressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention
The Accountable Community for Health of King County Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention May 7, 2018 1 Opiate Treatment & Overdose Prevention Project Goal Immediate:
More informationIdentification and Treatment of Opioid Use Disorders in Primary Care Settings
Identification and Treatment of Opioid Use Disorders in Primary Care Settings 17th Annual Primary Care Symposium February 24, 2018 Kelly S. Barth, DO Associate Professor, Psychiatry & Internal Medicine
More informationRates of Opioid Overdose Deaths, Sales, and Treatment Admissions: US,
Rates of Opioid Overdose Deaths, Sales, and Treatment Admissions: US, 1999 21 8 Rates of Prescription Painkiller Sales, Deaths, and Substance Abuse Treatment Admissions (1999 21) 7 Rate 6 5 4 3 Sales per
More informationMedical Assisted Treatment of Opioid
Medical Assisted Treatment of Opioid Dependence with XR-NTX(Vivitrol) Michael McNamara DO, FACN Medical Director Mental Health Center of Greater Manchester Manchester NH Outline Overview of Opioid Dependence
More informationWasted AN INTRODUCTION TO SUBSTANCE ABUSE
Wasted AN INTRODUCTION TO SUBSTANCE ABUSE Dr. Brian L. Bethel Child and Family Therapist Independent Trainer and Consultant LPCC-S, LCDC III, RPT-S www.brianlbethel.com INTERPLAY COUNSELING & CONSULTING
More informationLatest Research on Addiction and Treatment
Latest Research on Addiction and Treatment Joshua D Lee MD MSc joshua.lee@nyumc.org / @DrJoshuaDLee Associate Professor NYU School of Medicine, Department of Population Health Disclosures, LeeJD Grants:
More informationOpioid dependence and buprenorphine treatment
Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance
More informationGOALS AND OBJECTIVES
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
More informationWhat Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016
What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)
More informationROSC & MAT II: Opioid Treatment Services
ROSC & MAT II: Opioid Treatment Services September 23, 2015 Stan DeKemper Executive Director Indiana Credentialing Association on Addiction and Drug Abuse 1 GOALS Review medication assisted recovery Identify
More informationOpioids Research to Practice
Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose
More informationSANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery
Page 1 of 9 SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery Departmental Polley and Procedure Section Sub-section Alcohol and Drug Program (ADP) Effective: 7/11/2018
More informationOpioid Management of Chronic (Non- Cancer) Pain
Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are
More informationPublic Policy Statement on the Regulation of Office-Based Opioid Treatment
Public Policy Statement on the Regulation of Office-Based Opioid Treatment Background Office-based opioid treatment (OBOT) commonly refers to outpatient treatment services provided outside of licensed
More informationAppendix F Federation of State Medical Boards
Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationOpioids Research to Practice
Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education
More information9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare
Buprenorphine Treatment (Suboxone) Selahattin Kurter, MD Spectrum Healthcare Board Certified in Psychiatry and Addiction Medicine Disclosures No financial reimbursement for this lecture Consultant for
More informationInterdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings
Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings BRIAN GARVEY, MD, MPH REBECCA CANTONE, MD OREGON HEALTH & SCIENCE UNIVERSITY SCAPPOOSE RURAL HEALTH CENTER Disclosures
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationMedication-Assisted Treatment (MAT) for Opioid Use Disorders
Medication-Assisted Treatment (MAT) for Opioid Use Disorders Sybil Marsh MA MD FASAM Department of Family Medicine and Community Health Case Western Reserve University/UHCMC Learning Objective 1 Following
More informationSerious Mental Illness and Opioid Use Disorder
Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorders Arthur Robin Williams, MD MBE Columbia University, Department of Psychiatry Nick Szubiak, MSW, LCSW Director,
More informationPharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco
Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid
More informationClinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version
Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of
More informationFighting Today s Opioid Epidemic
Fighting Today s Opioid Epidemic Establish in 1966 as a Public Health Department Location: Rock Falls, IL/Whiteside County Population: Whiteside County 2015--57,079 Serving Rural IL: Primarily Whiteside,
More informationHARM REDUCTION & TREATMENT. Devin Reaves MSW
HARM REDUCTION & TREATMENT Devin Reaves MSW The mission of PAHRC is to promote the health, dignity, and human rights of individuals who use drugs and communities impacted by drug use. Recognizing that
More informationCDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control
CDC Guideline for Prescribing Opioids for Chronic Pain Centers for Disease Control and Prevention National Center for Injury Prevention and Control THE EPIDEMIC Chronic Pain and Prescription Opioids 11%
More informationBuilding capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
More informationPregnancy, MAT and Addiction
Pregnancy, MAT and Addiction Carl Christensen, MD, PhD, D-FASAM Clinical Associate Professor, OB Gyn & Psychiatry Wayne State University School of Medicine William Morrone, DO, MPH, DABAM Covenant Hospital
More informationOpioid Stewardship and Managing the Opioid Crisis: A Health-Care Perspective
Opioid Stewardship and Managing the Opioid Crisis: A Health-Care Perspective February 13, 2018 Frank Vocci, PhD New Therapies on the Horizon The planners, editors, faculty and reviewers of this activity
More informationGuidance for naltrexone prescribing
Document level: Drug Alcohol (Trustwide) Code: DA7 Issue number: 2 Guidance for naltrexone prescribing Lead executive Authors details Type of document Target audience Document purpose Lead Clinical Director
More informationHospitals Role in Addressing the Opioid Crisis
Hospitals Role in Addressing the Opioid Crisis Webinar 5: Buprenorphine in the Emergency Department November 14, 2017 Agenda Hospital Based Buprenorphine Initiatives Yngvild Olsen, M.D., Medical Consultant,
More informationVivitrol Vs. Suboxone
Vivitrol Vs. Suboxone Vivitrol - Naltrexone Indicated for opiate dependence and alcohol withdrawal pure antagonist 380mg once every 4 weeks IM Peak plasma concentration in 2 hrs, followed by a second peak
More informationManagement of Opioid Use Disorder in Primary Care
1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,
More informationBuprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17
+ Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient
More informationRI Centers of Excellence for the
RI Centers of Excellence for the Treatment of Opioid Use Disorder COE CODAC Behavioral Healthcare Linda Hurley President/CEO 9-18-17 for the Warren Alpert Medical School of Brown University RI s Strategic
More informationMedication for the Treatment of Alcohol Use Disorder. Pocket Guide
Medication for the Treatment of Alcohol Use Disorder Pocket Guide Medications are underused in the treatment of alcohol use disorder. According to the National Survey on Drug Use and Health, of the estimated
More informationQuestions & Answers About Probuphine. Here are the answers to some questions you may have about the Probuphine implant:
Questions & Answers About Probuphine Here are the answers to some questions you may have about the Probuphine implant: 1. Can my doctor prescribe and insert Probuphine? 2. What should I do after the Probuphine
More informationOpioid Use Disorders &Medication Treatment
Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review
More informationTreating Opioid Addiction
Treating Opioid Addiction Some people who start taking opioid pain medications eventually have serious problems with them and become addicted. Every day, 68 people die in the US from opioid overdose. More
More informationMedication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc.
Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc. Elements Behavioral Health Diplomate, American Board of Addiction
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationThe available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs
More informationMAT - ICAAD 2018 Ron Jackson, MSW, LICSW
The ATTC Network Ten Regional Centers northwest@attcnetwork.org www.attcnetwork.org/northwest phone. 206-685-4419 1107 NE 45 th St, Ste 120, Seattle, WA 98105 http://attcnetwork.org/northwest U.S. Opioid
More informationIn 2008, an estimated 282,000 persons
National Survey of Substance Abuse Treatment Services The N-SSATS Report January 28, 2010 Similarities and Differences in Opioid Treatment Programs that Provide Methadone Maintenance or Buprenorphine Maintenance
More informationSUBSTANCE USE DISORDER TREATMENT AND REFERRAL PROCESS
SUBSTANCE USE DISORDER TREATMENT AND REFERRAL PROCESS Presented by: John M. Connolly, Ph.D. Acting Deputy Director Los Angeles County Health Agency Department of Public Health Substance Abuse Prevention
More informationBUPRENORPHINE. THERAPEUTICS Brands Suboxone (with naloxone) Probuphine (implant) see index for additional brand names
BUPRENORPHINE THERAPEUTICS Brands Suboxone (with naloxone) Probuphine (implant) see index for additional brand names Generic? Yes (not for with naloxone or implant) Class mu opioid receptor partial agonist
More information2/21/2018. What are Opioids?
Opioid Crisis: South Carolina Responds Carolyn Bogdon, MSN, FNP-BC Coordinator for Emergency Department Medication Assisted Treatment Program Medical University of South Carolina Opioid Crisis: A Mounting
More informationBUPRENORPHINE (PROBUPHINE & SUBLOCADE )
UnitedHealthcare Oxford Clinical Policy BUPRENORPHINE (PROBUPHINE & SUBLOCADE ) Policy Number: PHARMACY 291.6 T2 Effective Date: July 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS
More informationfor Opioid Dependence Buprenorphine/Naloxone Bunavail TM Suboxone Film Zubsolv Policy Number: MCP-072 Revision Date(s): 2/25/13; 4/4/17
Subject: Buprenorphine/Naloxone and Buprenorphine Original Effective Date: 8/26/09 for Opioid Dependence Buprenorphine/Naloxone Bunavail TM Suboxone Film Zubsolv generic Buprenorphine/Naloxone sublingual
More informationOpioid Dependence and Buprenorphine Management
Opioid Dependence and Buprenorphine Management Kevin Kapila, MD Fenway Health Medical Director of Behavioral Health Instructor in Medicine Harvard Medical School Learning Objectives Understand the rationale
More information